Most cancer genomics data comes from Western populations. Treatments designed on that data don't always work for Indian patients. This is not a research gap. It's a clinical reality affecting millions.

India's genomic diagnostics market in oncology was ₹250 crore in 2023. And for a company willing to build the infrastructure to make precision oncology work for Indian patients, the runway extends well beyond oncology into adjacent therapeutic areas and geographies.

4basecare is doing exactly that. They've built TarGT Indiegene, the world's first Indian population-specific cancer gene panel, covering 1,212 genes with 600 locally relevant additions. This isn't a tweaked Western product. It's ground-up development based on data from Indian patients.

Over 20,000 patients tested. 65% actionability in lung cancer. Expanding presence across Dubai and the Philippines. When NR Narayana Murthy inaugurated their new Bengaluru genomics lab and unveiled the Global Cancer Diversity Atlas, it marked something bigger than a facility launch. It was a statement that genomic data from India and the Global South will finally be represented in global cancer research.

What convinced us was the intersection of science and clinical pathway. 4basecare isn't building for research grants. They're building sustainable diagnostics businesses with clear paths to adoption and reimbursement.

Precision oncology in India needed a company like this. We're glad to be part of the journey.